https://mindmedicinelaw.com/briefing/biomarkers-in-bipolar-disorder-ketamine-psychedelics-20260728-26887The Psychedelic Journalen2026-07-28T22:06:02.896903+00:00Biomarkers in Bipolar Disorder: Ketamine & Psychedelicsbipolar disorder, biomarkers, ketamine, psychedelic interventions, clinical trials, precision medicine, patient outcomes, psychiatric treatment, neuroscience, public healthhttps://mindmedicinelaw.com/briefing/hepatic-safety-of-ketamine-in-depression-treatment-new-insights-20260728-26920The Psychedelic Journalen2026-07-28T22:05:54.773163+00:00Hepatic Safety of Ketamine in Depression Treatment: New Insightsketamine, esketamine, hepatic safety, treatment-resistant depression, clinical guidelines, liver function, psychiatric treatmenthttps://mindmedicinelaw.com/briefing/fda-pediatric-advisory-committee-meeting-implications-for-psychedelic-research-20260728-26614The Psychedelic Journalen2026-07-28T15:06:11.997235+00:00FDA Pediatric Advisory Committee Meeting: Implications for Psychedelic ResearchFDA Pediatric Advisory Committee, psychedelic research minors, pediatric psychedelic therapies, FDA public meeting, psychedelic regulatory issues, pediatric clinical trials, psychedelic safety children, public health policy psychedelicshttps://mindmedicinelaw.com/briefing/psilocybin-microdosing-for-depression-current-evidence-review-20260727-26805The Psychedelic Journalen2026-07-28T22:06:39.550625+00:00Psilocybin Microdosing for Depression: Current Evidence Reviewpsilocybin microdosing, depression treatment, psychedelic research, clinical trials, mental health, methodological limitations, serotonin receptors, placebo effects, ethical considerations, psychedelic therapieshttps://mindmedicinelaw.com/briefing/eeg-spectral-power-decodes-ketamine-state-implications-for-research-20260726-26843The Psychedelic Journalen2026-07-28T22:06:22.147233+00:00EEG Spectral Power Decodes Ketamine State: Implications for ResearchEEG spectral power, ketamine state decoding, phase connectivity, psychedelic research, neural correlates, EEG-based diagnostics, subanaesthetic ketamine, consciousness, cross-subject transferability, psychedelic stateshttps://mindmedicinelaw.com/briefing/ketamine-s-role-in-treating-depression-in-bpd-a-review-20260726-26857The Psychedelic Journalen2026-07-28T22:06:11.575742+00:00Ketamine's Role in Treating Depression in BPD: A Reviewketamine, borderline personality disorder, depression, suicidality, clinical trials, psychedelic research, mental health, pharmacology, NMDA receptor, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/elunetirom-s-role-in-enhancing-neuroplasticity-explored-20260725-26859The Psychedelic Journalen2026-07-28T22:06:30.618306+00:00Elunetirom's Role in Enhancing Neuroplasticity Exploredelunetirom, neuroplasticity, thyroid hormone receptor, major depressive disorder, bipolar depression, mitochondrial biogenesis, psychiatric disorders, clinical trials, brain-targeted therapy, thyromimetic signalinghttps://mindmedicinelaw.com/briefing/insights-from-psychedelic-clinical-trial-design-review-20260725-26399The Psychedelic Journalen2026-07-27T15:05:44.636561+00:00Insights from Psychedelic Clinical Trial Design Reviewpsychedelic clinical trials, trial design, psychedelic research, clinical methodologies, adaptive trial design, research protocols, psychedelic therapies, long-term effects, safety protocols, scientific rigorhttps://mindmedicinelaw.com/briefing/trump-s-executive-order-and-its-impact-on-psychedelic-therapy-20260722-26585The Psychedelic Journalen2026-07-27T22:04:02.298858+00:00Trump's Executive Order and Its Impact on Psychedelic Therapypsychedelic therapy, executive order, Trump, regulatory processes, FDA, DEA, mental health treatment